Subcutaneous Extended-Release Buprenorphine Use in Pregnancy

Table 2

Urine buprenorphine and norbuprenorphine levels for patient two obtained through gestation, at delivery, and 6 weeks postdelivery—the last administration of subcutaneous extended-release buprenorphine was at the time of her last menstrual period.

Gestational age; (weeks)	Buprenorphine level; (ng/mg creatinine)	Norbuprenorphine level; (ng/mg creatinine)
9^3/7	73	46
14^2/7	54	33
18^2/7	19	19
25^2/7	8	11
28^2/7	3	6
30^2/7	4	0
33^2/7	5	0
Delivery 37^4/7	1	0
6 weeks postdelivery	0	0